FDA Approves First Of New Type Of Generic Drugs
The Food and Drug Administration has approved the first in a class of generic drugs that are made from living cells instead of chemical compounds.
So-called biosimilar drugs "are complex medications made or extracted from living cells, blood components and tissue," The Wall Street Journal says.
The newspaper adds: "Biosimilars, unlike traditional generics, aren't precisely identical to the brand drug.
The FDA says biosimiliars must have no "clinically meaningful differences" in safety or effectiveness and must work in the same way as the drugs they are meant to substitute.
The FDA said Friday it has approved the first biosimilar, a drug called Zarxio that is made by Novartis AG's Sandoz unit and meant to boost white blood cells in chemotherapy patients.
As NPR's Rob Stein reports, the decision is expected to open the door to getting many more, less costly versions of expensive drugs on the market.
Zarxio is a generic version of a drug that costs more than $3,000 for a one-month regimen. The biosimilar version costs about $1,000.
Rob notes: "That may not sound like a lot. But the drug's used a lot. So, according to one estimate, the cheaper, generic version could save the U.S. health care system nearly $6 billion over the next decade."
http://www.npr.org/blogs/thetwo-way/2015/03/06/391237185/fda-approves-first-of-new-type-of-generic-drugs

Providing the public with generic, less costly medications, of this or the regular kind of generic, will go a long way to making health more affordable for the working class of the U.S.
I have first hand experience with the cost of chemo and chemo related medications and the cost are incredibly high. Some insurance coverage, mine is one, provides generic maintenance medications virtually free of cost to the consumer and all generics at very low co-pays.
The expansion of the number of generic medications available to the public and speeding up the availability of generic alternatives is crucial to making health care more affordable
I'm all for this-- as long as the generic drugs work. Sometimes, they aren't as effective as the Real McCoy.
This sounds like a great idea!
Sometimes, a change of ingredients can have unintended consequences. Like a person who is sensitive to the dyes used to differentiate brands. Or a buffer used a formulation can cause reactions not seen in the "Real McCoy".
Dowser
I agree the standards for the generics must be as high (we could hope for higher) than the original drugs for effectiveness and as low on side effects
We pay so much for the "brand" name and it is important that the companies recover their R&D costs but there has to be a limit to when that occurs.
Appreciate the feedback
O M
You are right of course, but there are also probably instances where the generics are more effective and have less side effects, we just don't see Big Pharma publicizing those cases
Thanks for the feedback and perspective
Oh yes... Sometimes, the generic brands just don't work as well, but if they do, I certainly use them!
I think they recover those costs, sometimes, 1000-fold...
The argument is that profit goes into new research and sometimes that research is fruitless or takes longer than expected, but I agree the length of time that the drug patents extend is way too long.
The generic drugs are cheaper and must get to the market sooner.
The companies get tax breaks for R&D as it is
If ya want an education of high standards in generics, Google the company Ranbaxy Laboratories.
O M
Thanks for that info I will heck it out
I have always contended that there are several aspects of the PPACA that were good things and that overall the PPACA was a small step towards the goal which is health care reform and cosr reductions for the consumer
Thanks for the perspective